The College of Science at the University of Basra organized a seminar on the production of nanoscale antibodies against the CD19 immune receptors that are abundant on the surfaces of B-lymphocytes for graduate student Samar Kazem Yusef. The study included the use of a German experimental animal of American origins and its immunization with the CD19 antigen, which is considered to be a sign of cancerous diseases.
The study recommended that, as long as the preparation of nanoscale antibodies has become possible in Iraqi laboratories, it is recommended to use them as a new therapeutic approach to treat B lymphoma and autoimmune diseases by producing and establishing a drug delivery system to transport it to the target cell.